CERo Therapeutics Holdings, Inc. operates as an immunotherapy firm, concentrating its efforts on developing cutting-edge engineered T-cell therapies designed to combat cancer. Its primary therapeutic initiative addresses blood cancers, specifically by aiming to counteract a particular "Eat Me" signaling mechanism that is significantly overexpressed on both B-cell and myeloid tumor cells. The company's corporate headquarters are situated in South San Francisco, California.